Customers also like
Hostacycline (Tetracycline) - 500mg (15 Capsules)
our best price : $3.68
Rcifax 400 (Rifaximin) - 400mg (10 Tablets)
our best price : $11.02
* Quantity
1-9 Strip(s)
10-19 Strip(s)
20-39 Strip(s)
40 Strip(s) +
Price / Each
$2.41
$2.29
$2.24
$2.17
Description
Imodium (Loperamide Hydrochloride) is indicated for the control and symptomatic treatment of acute nonspecific diarrhoea, chronic diarrhoea, and reducing the volume of discharge in patients with ileostomies, colostomies, and other intestinal resections.
Imodium (Loperamide Hydrochloride) capsules are administered orally with the aid of liquid. The recommended initial dose in adults treating acute diarrhea is two capsules (4 mg) followed by one capsule (2 mg) after each unformed stool. Daily dose should not exceed eight capsules or caplets or tablets (16 mg). Clinical improvement is usually observed within 48 hours.
The recommended initial dose for chronic diarrhea and reduction in volume of discharge of intestinal resections is two capsules (4 mg) followed by one capsule (2 mg) after each unformed stool until diarrhea is controlled, after which dosage should be reduced to meet individual requirements. When the optimal maintenance daily dosage has thus been established, this amount can then be administered as a single dose or in two or three divided doses.
The average daily maintenance dosage in clinical trials was two to four capsules (4mg to 8 mg). A dosage of five capsules (10 mg) was rarely exceeded. A temporary exacerbation of diarrhea was controlled by increasing the dosage to achieve further control followed by titration back to the established maintenance dose.
Some patients taking Imodium (Loperamide Hydrochloride) may notice:
- Dryness in the mouth
- Dizziness
- Stomach distention
- Constipation
- Tiredness
Use in patients with hepatic impairment: Imodium (Loperamide Hydrochloride)should be used with caution in patients with hepatic insufficiency because of reduced first pass metabolism. Patients with hepatic dysfunction should be monitored closely for signs of central nervous system (CNS) toxicity.
Use in patients with renal impairment: since the majority of the drug is metabolised, and the metabolites or the unchanged drug is excreted in the faeces, dose adjustments in patients with a kidney disorder are not required.
